# Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)

> **NCT00564421** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 798 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** epinastine nasal spray, low concentration, low dose volume
- **OTHER:** placebo nasal spray
- **DRUG:** epinastine nasal spray, low concentration, high dose volume
- **DRUG:** epinastine nasal spray, high concentration, low dose volume
- **DRUG:** epinastine nasal spray, high concentration, high dose volume

## Key facts

- **NCT ID:** NCT00564421
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-18
- **Primary completion:** 2008-02-14
- **Final completion:** 2008-02-14
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2017-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00564421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00564421, "Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00564421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*